Shots:

• The test provides standardized results to assess the risk of complications caused by the BK virus in transplant patients and identify effective treatment options
• It has received FDA’s BDD for improved treatment/diagnosis of life-threatening diseases for transplant patients. The approval allows Roche to offer HCPs a transplant testing portfolio that includes Cytomegalovirus- Epstein-Barr virus- and BK virus to monitor and improve care for transplant patients
• The cobas BKV Test is a fully automated PCR viral load test that runs on cobas 6800/8800 Systems and has a robust coverage with a detection limit (21.5 IU/mL) and an expanded linear range (21.5 IU/mL to 1E+08 IU/mL) in EDTA plasma

­ Ref: Roche | Image: Roche